Navigation Links
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

SALT LAKE CITY, Aug. 4 /PRNewswire/ -- ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Erbitux/Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13," and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these mutations.

ARUP offers leading-edge KRAS mutation-detection testing in colon-cancer patients which can identify nearly all of the patients who will not benefit from taking either Vectibix or Erbitux. These drugs cost tens of thousands of dollars per course of therapy and simply running ARUP's KRAS mutation-detection test can potentially eliminate ineffective patient treatment and decrease health care expenses. ARUP's technical bulletin, "KRAS Mutation Detection in Colorectal Cancer; For Determining Mutational Status that Confers Resistance to Anti-EGFR Therapy," elaborates on this testing and can be found at

"In the United States, colorectal cancer is the third most common form of cancer and individuals have a 6 percent lifetime risk of developing this disease," said Executive Vice President of Corporate Communications Ronald L. Weiss, MD, MBA. "Our goal is to help our clients improve patient care as well as reduce unnecessary expenditures by promoting the benefits of KRAS testing."

KRAS mutation-detection assays test colorectal cancer to determine whether a particular therapeutic strategy should be used by oncologists. Most colorectal cancer is caused by somatic mutations and is not hereditary. Mutations in the oncogene KRAS are seen in over 40 percent of sporadic colorectal cancers. While several laboratories in the United States offer this test, ARUP Laboratories' KRAS assay detects all 12 mutations at codons 12 and 13; another highly publicized assay on the market detects only seven.

KRAS mutation-detection testing is just one example of how ARUP Laboratories can partner with laboratories and hospitals to improve patient care and decrease overall health care costs by helping reduce over-, under-, and misuse of laboratory tests. To learn more about how ARUP Laboratories can help your laboratory, please visit

About ARUP Laboratories

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 2,600 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients nationwide. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics. ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical & Experimental Pathology(R). Further information on ARUP Laboratories can be found at

SOURCE ARUP Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Creighton Medical Laboratories First to Offer New Cancer Test
2. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
3. IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729
4. Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
6. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
7. Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
8. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
9. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
10. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
Breaking Medicine News(10 mins):